EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

First‐Generation TTR Silencing Therapies in Hereditary Transthyretin Amyloidosis With Polyneuropathy: Real‐World Insights From a German Single‐Referral Center

Marilin S Koch iD, Fabian Aus dem Siepen iD, Ute Hegenbart iD, Stefan Schönland iD, Markus Weiler iD

European Journal of Neurology · 2026

DOI: 10.1111/ene.70529 ↗

At a glance

Journal article in European Journal of Neurology, 2026. Written by Marilin S Koch and 4 co-authors. Institution: Amyloidosis Center, Heidelberg University Hospital, and Faculty of Medicine, Heidelberg University, Heidelberg, Germany. Major MEDLINE topics: Amyloid Neuropathies, Familial, Prealbumin, Polyneuropathies. Cited 1 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Hereditary transthyretin (ATTRv) amyloidosis is a rare, genetically heterogeneous disease leading to an unstable configuration of transthyretin (TTR) and hence irregular deposition of TTR amyloid fibrils. The disease predominantly affects the peripheral nervous system, resulting in a progressive sensorimotor polyneuropathy (ATTRv‐PN), but can also involve the cardiac and other organ systems. The TTR mRNA silencers patisiran and inotersen effectively reduce serum TTR levels, thereby improving neurologic disability and quality of life in patients with ATTRv‐PN. This real‐world study investigated long‐term efficacy and tolerability of both compounds in patients with ATTRv‐PN.

Methods

This retrospective study from a German single‐referral center assessed the effects of treatment with patisiran or inotersen on clinical parameters of 35 patients with ATTRv‐PN treated at the Amyloidosis Center of Heidelberg University Hospital for up to 6 years after therapy start. The study included analyses of serum TTR levels, NT‐proBNP, creatinine and modified body mass index (mBMI), and reported side effects throughout the observational period.

Results

Both silencers stably reduced serum TTR levels by 81.1% ( p = 0.0039, patisiran) and 82.8% ( p = 0.0039, inotersen), respectively, after 8 to 15 months compared to mean baseline. NT‐proBNP, creatinine, and mBMI values remained stable during treatment. With patisiran, a lower rate of reported adverse effects was observed. Grade 1 thrombocytopenia was reported primarily for inotersen‐treated patients.

Conclusions

Our findings confirm long‐term treatment with TTR silencers in a real‐world setting is safe, consistently reducing serum TTR levels, stabilizing neurologic symptoms, cardiac and renal functions, and nutritional parameters.

Subjects

MeSH terms (MEDLINE)

Amyloid Neuropathies, FamilialPrealbuminPolyneuropathiesHumansFemaleMaleRetrospective StudiesGermanyMiddle AgedAgedTreatment OutcomeOligonucleotidesRNA, Small Interfering

Author keywords

ATTRv amyloidosisGermanyTTR silencerinotersenpatisiran

Substances

PrealbuminpatisiranInotersenTTR protein, humanOligonucleotidesRNA, Small Interfering

Authors and institutions

  • Amyloidosis Center, Heidelberg University Hospital, and Faculty of Medicine, Heidelberg University, Heidelberg, Germany.
  • Department of Neurology, Heidelberg University Hospital, and Faculty of Medicine, Heidelberg University, Heidelberg, Germany.
  • Department of Cardiology, Heidelberg University Hospital, and Faculty of Medicine, Heidelberg University, Heidelberg, Germany.
  • Department of Medicine V, Heidelberg University Hospital, and Faculty of Medicine, Heidelberg University, Heidelberg, Germany.

ORCID profiles: Marilin S Koch, Fabian Aus dem Siepen, Ute Hegenbart, Stefan Schönland, Markus Weiler

Cite

APA

Koch, M. S., Siepen, F. A. D., Hegenbart, U., Schönland, S., & Weiler, M. (2026). First‐Generation TTR Silencing Therapies in Hereditary Transthyretin Amyloidosis With Polyneuropathy: Real‐World Insights From a German Single‐Referral Center. European Journal of Neurology. https://doi.org/10.1111/ene.70529

Vancouver

Koch MS, Siepen FAD, Hegenbart U, Schönland S, Weiler M. First‐Generation TTR Silencing Therapies in Hereditary Transthyretin Amyloidosis With Polyneuropathy: Real‐World Insights From a German Single‐Referral Center. European Journal of Neurology. 2026. doi:10.1111/ene.70529

BibTeX
@article{Koch2026,
  author = {Koch, Marilin S and Siepen, Fabian Aus dem and Hegenbart, Ute and Schönland, Stefan and Weiler, Markus},
  title = {First‐Generation TTR Silencing Therapies in Hereditary Transthyretin Amyloidosis With Polyneuropathy: Real‐World Insights From a German Single‐Referral Center},
  journal = {European Journal of Neurology},
  year = {2026},
  doi = {10.1111/ene.70529}
}
Start for free →